Systemic gaps in rare disease care: Age-based approvals and policy failures leave adults without life-saving treatments
Original framing: “Opinion: My brother can’t access a just-approved breakthrough drug for his rare disease” — STAT News
The original framing omits the historical exclusion of adults from rare disease research, the role of pharmaceutical pricing in limiting access, and the lack of patient advocacy representation for adult rare disease communities. Indigenous and non-Western perspectives on chronic illness and intergenerational care are ignored, as are the economic burdens on families navigating fragmented healthcare systems. Structural racism in medical research, which often understudies diseases affecting racial minorities, is also absent.
Medium structural omission detected in mainstream coverage.
The narrative is produced by STAT News, a platform catering to biomedical elites, policymakers, and industry stakeholders, reinforcing a pediatric-centric healthcare paradigm that aligns with pharmaceutical profit motives. The framing serves regulatory bodies and drug developers by shifting blame to 'systemic inefficiencies' while obscuring their role in designing exclusionary approval pathways. Marginalized patient groups—particularly adults with rare diseases—are sidelined in these discussions, despite bearing the brunt of policy failures.
The exclusion of adults from rare disease research stems from mid-20th-century pediatric dominance in clinical trials, a legacy of the thalidomide scandal that prioritized child safety over adult efficacy. Regulatory frameworks like the Orphan Drug Act (1983) were designed to incentivize pediatric research, inadvertently creating a structural bias against adult rare disease treatments. Historical case studies, such as the delayed approval of enzyme replacement therapies for adult Hunter syndrome, reveal how policy inertia perpetuates inequities.
The exclusion of adults from rare disease treatments is a structural failure rooted in mid-20th-century pediatric dominance in medical research, compounded by regulatory frameworks that prioritize child safety over adult access.